Company HST5040 Patients Pipeline Platform News Careers The HemoShear Advantage Disease Models Featured Publications The HemoShear Advantage The biopharmaceutical industry’s drug development success is impeded by a lack of physiological models that reflect the complexity of disease. HemoShear’s proprietary REVEAL-Tx™ platform combines biological and computational models of human disease to accelerate discovery of novel targets and successful new drug treatments. Disease Models HemoShear’s platform has been used to recreate nearly 20 human diseases related to liver, vascular and tumor biology, including those driving our current pipeline in several rare metabolic disorders and partnerships with major biopharma. Liver System Tumor System Vascular System HemoShear has created a biologically responsive human liver system that has yielded a number of novel targets that modulate processes associated with several metabolic diseases. We are advancing proprietary treatments for inborn errors of metabolism, including propionic academia, methylmalonic acidemia and maple syrup urine disease. We are also collaborating with Takeda to advance novel treatments for nonalcoholic steatohepatitis (NASH)/fibrosis and an undisclosed rare liver disease, and with Horizon Therapeutics for gout. Read More » Featured Publications HemoShear has more than 30 publications validating our platform in a range of scientiﬁc applications. For more information, contact info@hemoshear.com. Company HST5040 Patients Pipeline Platform News Careers info@hemoshear.com 501 Locust Avenue Suite 301 Charlottesville, Virginia 22902 © 2021 HemoShear Therapeutics, Inc. | Legal | Privacy | Contact

Company HST5040 Patients Pipeline Platform News Careers Tackling Rare Metabolic Disorders Pipeline HemoShear is developing proprietary new treatments for rare inborn errors of metabolism. We are also utilizing our transformational models of complex diseases to accelerate our partners’ programs in NASH, gout and an undisclosed rare liver disease. New Hope Needed There are currently no effective treatments for many inborn errors of metabolism, which can lead to severe organ damage, developmental deficits and premature death. Partnerships HemoShear’s exclusive partners are accelerating their drug discovery initiatives by leveraging our REVEAL-Tx™ disease modeling platform to identify and validate novel approaches to diseases. Partnering with HemoShear HemoShear seeks strategic partners that want to accelerate their drug discovery and development. If you are interested in partnering with HemoShear, please contact us at BusinessDevelopment@hemoshear.com. Company HST5040 Patients Pipeline Platform News Careers info@hemoshear.com 501 Locust Avenue Suite 301 Charlottesville, Virginia 22902 © 2021 HemoShear Therapeutics, Inc. | Legal | Privacy | Contact